Global Herpes Labialis Drugs Market - 2024-2031

Global Herpes Labialis Drugs Market - 2024-2031

The global herpes labialis drugs market reached US$ 1.16 billion in 2023 and is expected to reach US$ 1.7 billion by 2031 growing with a CAGR of 4.8% during the forecast period 2024-2031.

Herpes labialis, also termed as cold sores usually appears near the mouth or on other areas of the face. Cold sores are caused by herpes simplex virus type 1 (HSV-1) but occasionally by herpes simplex virus type 2 (HSV-2). The herpes labialis virus is usually transmitted through non-sexual contact between individuals, and outbreaks can be triggered by exposure to sunlight, fever, stress, or menstrual cycles.

The global herpes labialis drug market has grown significantly in recent years due to adopting episodic treatment for recurrent herpes labialis. For instance, in immunocompetent patients, Acyclovir 200-400 mg is taken 5 times a day for 5 days, Valacyclovir 2000 mg every 12 hours for 1 day, and Famciclovir 1500 mg as a single dose, and also oral antiviral medication, topical creams & ointment, and immunomodulators.

Market Dynamics: Drivers

Increasing product launches and rising fda approvals of drugs for herpes labialis drugs

The demand for the global herpes labialis drugs market is driven by multiple factors. One of the primary factors is the increasing product launches and rising FDA approvals of drugs for herpes labialis treatment.

Herpes simplex virus primarily spreads by skin-to-skin contact and is treatable but not curable. Herpes labilalis usually affects the mouth area which causes small, painful blisters to develop on the lips, gums, or throat.

Moreover, key players in the market focus on the treatment of herpes labialis, and innovative product launches and approvals would propel this market growth. These effective product launches help to transform research discoveries into new treatments and improve care for millions of people with herpes labialis.

For instance, in May 2023, Outbreaks Inc. announced the launch of AZZURX, an innovative topical therapy for cold sores and fever blisters. This therapy comprises four active botanical homeopathic ingredients suspended in a proprietary blend of rare natural essential oils. AZZURX is formulated to stop outbreaks before they erupt, shorten active outbreaks, and promote healing while reducing discomfort.

Also, in March 2023, Zydus Lifesciences Ltd. announced that it has received final approval from the United States Food and Drug Administration (U.S FDA) for Acyclovir Cream 5% which is used to treat cold sores on the face and lips. Acyclovir belongs to a class of medicines known as antivirals.

Restraints

Factors such as antiviral drug resistance, side effects associated with the treatment of drugs, limited availability of effective vaccines, high cost of the treatment, and lack of awareness among individuals are expected to hamper the market.

Segment Analysis

The global herpes labialis drugs market is segmented based on strain type, drug type, route of administration, distribution channel, and region.

The acyclovir segment accounted for approximately 56.5% of the global herpes labialis drugs market share

The acyclovir segment is expected to hold the largest market share over the forecast period. Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes.

Moreover, key players in the industry launching new drugs and approvals for acyclovir are expected to boost the segment's market growth. For instance, in May 2023, Modavar Pharmaceuticals announced that it had launched Acyclovir Capsules. The launch of the 200mg strength of Acyclovir adds to the growing line of products in the Modavar portfolio. The product is available immediately and is AB-rated to Mylan’s Zovirax. It is indicated for the treatment of Cold Sores (caused by Herpes Simplex, HSV-1), Shingles (caused by Herpes Zoster), Genital Herpes (HSV-2), and Chickenpox.

Also, in October 2022, Camber Pharmaceuticals introduced Acyclovir Oral Suspension and extended its current portfolio. Acyclovir Oral Suspension is an artificial nucleoside analog functional in herpes virus treatment.

In addition, the rising number of clinical trials in the treatment of herpes labialis would drive this segment's growth. According to clinicalTrials.gov, in July 2023, Bayer conducted a clinical trial on the study to compare sitavig (acyclovir) buccal tablet with a placebo in the treatment of herpes labialis in immunocompetent adults.

Geographical Analysis

North America accounted for approximately 43.2% of the global herpes labialis drugs market share

North America region is expected to hold the largest market share over the forecast period. The rising prevalence and incidence of herpes simplex virus infection across the globe act as a primary driver for the herpes labialis drug market. According to WHO data in August 2023, an estimated 3.7 billion people under age 50 (67%) globally have herpes simplex virus type 1 (HSV-1) infection which is the main cause of oral herpes. Also, an estimated 491 million people aged 15–49 (13%) worldwide have herpes simplex virus type 2 (HSV-2) infection which is the main cause of genital herpes.

Moreover, in this region, major key players are presence, increasing FDA approvals for HSV-1 gene therapy, technological advancements, and rising research and developments in herpes labialis treatment.

For instance, in May 2023, the U.S. Food and Drug Administration approved Vyjuvek which is a herpes simplex virus type 1 (HSV-1) vector-based gene therapy. Vyjuvek is a genetically modified herpes-simplex virus used to deliver normal copies of the COL7A1 gene to wounds. Vyjuvek is mixed into an excipient gel before topical application.

Market Segmentation

By Stain Type
• Herpes Simplex Virus Type-1
• Herpes Simplex Virus Type-2

By Drug Type
• Acyclovir
• Valacyclovir
• Penciclovir
• Famciclovir
• Docosanol
• Others

Route of Administration
• Topical
• Oral
• Injectables

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the herpes labialis drugs market include GlaxoSmithKline Pharmaceuticals, Bauch Health Inc., Novartis AG, Zhejiang Charioteer Pharmaceutical Co. Ltd, Teva Pharmaceuticals, TCI Chemicals, Olon Group, ChemWerth Inc., Viatris Inc., and Tecoland Corporation among others.

Key Developments

In July 2023, Replimune Group, Inc. and Incyte announced a collaboration and supply agreement to study RP1, Replimune’s lead product in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. RP1 is Replimune’s lead oncolytic immunotherapy product candidate and is based on a proprietary new strain of herpes simplex virus engineered for tumor-selective replication.

In May 2023, Mylab Discovery Solutions launched PathoDetect for HSV Type 1& 2 Detection kit which is a multiplex real-time PCR test to detect and differentiate herpes simplex virus type I (HSV-l) and type 2 (HSV-2) in a single tube. It is approved by CDSCO and delivers high sensitivity and specificity in the detection of HSV-1 and HSV-2 DNA in clinical specimens.

In January 2023, Molbio Diagnostics announced that it had launched the Truenat HSV 1/2 for testing the Herpes Simplex Virus. The test is approved by CDSCO and can provide sample-to-test results. This real-time PCR test works on the existing Truelab infrastructure and does not require any additional setup and equipment to run the test.

In December 2022, BioNTech announced that the first subject was dosed in a first-in-human Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.

In August 2022, Rational Vaccines announced a clinical trial to determine baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex type 2 (HSV-2) virus.

Why Purchase the Report?
• To visualize the global herpes labialis drug market segmentation based on the strain type, drug type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the global herpes labialis drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global herpes labialis drugs market report would provide approximately 70 tables, 64 figures, and 182 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies